Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability
about
Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugsAdjuvant activity of CpG oligodeoxynucleotidesA dual drug sensitive L. major induces protection without lesion in C57BL/6 miceVaccines for the leishmaniases: proposals for a research agendaCancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infectionPrevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.Immunization with persistent attenuated Delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice.CpG DNA as a vaccine adjuvant.Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of leishmanization in mice.The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice.Recent advances in vaccines for leishmaniasis.The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.Adjuvants for Leishmania vaccines: from models to clinical application.Concomitant Immunity Induced by Persistent Leishmania major Does Not Preclude Secondary Re-Infection: Implications for Genetic Exchange, Diversity and Vaccination.Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue siteCutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantumCutaneous Leishmania infection: progress in pathogenesis research and experimental therapy.Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process.Vaccination with live Leishmania major and CpG DNA promotes interleukin-2 production by dermal dendritic cells and NK cell activationComparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains.The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides.Vaccine Development Against Leishmania donovani.Protective immunity and vaccination against cutaneous leishmaniasis.The generation of CD8+ T-cell population specific for vaccinia virus epitope involved in the antiviral protection against ectromelia virus challenge.Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice.The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model.
P2860
Q24811712-00E6DC39-D7A2-4C91-B037-C31DBA47CA87Q28250104-F17BB85E-8A18-414B-ACE1-FACDDF2135E3Q28539173-DD283725-E683-4BEC-8C4C-B235DB87CF87Q28741577-572C486B-B37E-4502-9F00-AE6C636E34E8Q33582300-24FA2BA2-AA19-4A7A-A5FD-EF3674C3C8E1Q33946585-B2366890-AF44-4E3B-A2B6-373DF2FF91D3Q33946716-A144E223-C40C-4E59-BB80-1589971DB356Q34033343-CAD33ABD-869C-4FAA-96CC-C92971068330Q34033949-95905905-227E-4E49-B046-204325364936Q34300949-D8570812-2D53-479D-B43B-B89D95EB3E53Q35025722-1C00DC3E-6FF7-4143-A3E2-08E47BD92791Q35571431-FB07D3BE-4D8F-42CE-A73A-9154147B15BEQ35757996-27B2B5F1-7A0F-4E9E-9316-F6C0F2A05C81Q35873792-19CCB77E-87B0-4C09-BA84-70995EF350A4Q35884264-A743B6D0-03E3-4BF1-95DA-D737849F4F25Q36021357-6CADA560-0F86-4E6C-950A-738B69E586AFQ36063251-57BD40F5-AA4D-425B-97DA-E9EA1687A09BQ36330876-1E8A7DE9-1D1F-4FBD-83D9-C80875630EFAQ36331305-0B953C2F-965D-4E22-9A0C-576430383D8EQ36759574-8E885195-0BF1-466D-AEF8-2C2B8B806EE3Q37310681-E6130E9E-290A-4E07-8DF7-05832E393A70Q37410025-575BD3A6-52A5-4C01-9610-9BBBFE0DAE4BQ37410053-BCB9E737-E865-42CE-A4DD-FB1E921F1A1CQ37415405-CD39234A-F6D8-44E0-B024-2AE7C3A0FC12Q38012112-4993E91C-B8D5-4235-9E61-5F5319418354Q38015852-AEF9CBC8-F9C5-4D1D-A498-873B5C89ED86Q40948671-898C7CE9-B0CF-4070-A648-A767923A63F3Q41383476-C69E1E00-4303-4D52-A6F6-16F11C817D87Q42670769-29492841-62BB-4AFB-845D-0F81A4567353Q50054197-EA129B47-6A42-49B7-AB32-AC15E3C9395F
P2860
Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Coinjection with CpG-containin ...... ins its potency and durability
@ast
Coinjection with CpG-containin ...... ins its potency and durability
@en
type
label
Coinjection with CpG-containin ...... ins its potency and durability
@ast
Coinjection with CpG-containin ...... ins its potency and durability
@en
prefLabel
Coinjection with CpG-containin ...... ins its potency and durability
@ast
Coinjection with CpG-containin ...... ins its potency and durability
@en
P2093
P2860
P1476
Coinjection with CpG-containin ...... ins its potency and durability
@en
P2093
Daniela Verthelyi
David L Sacks
Dennis Klinman
Khaled Tabbara
Robert A Seder
Susana Mendez
Sylvie Bertholet
P2860
P304
P356
10.1128/IAI.71.9.5121-5129.2003
P407
P577
2003-09-01T00:00:00Z